



Cite this: *Phys. Chem. Chem. Phys.*, 2024, 26, 28884

# Insights into the photoswitch based on 5-deazaFMN and LOV2 from *Avena sativa*: a combined absorption and NMR spectroscopy study†

Sabrina Panter,<sup>‡</sup> Jakob Wörner,<sup>‡,a</sup> Jing Chen,<sup>a</sup> Boris Illarionov,<sup>‡,b</sup> Adelbert Bacher,<sup>‡,c</sup> Markus Fischer<sup>‡,b</sup> and Stefan Weber<sup>‡,\*,a</sup>

The LOV2 domain from *Avena sativa* (As) is a blue light receptor that undergoes adduct formation with the native flavin mononucleotide (FMN) cofactor [Salomon *et al.*, *Biochemistry*, 2000, **39**, 9401]. We report the photochemical changes of AsLOV2 through cofactor exchange with the FMN analogue 5-deazaFMN. Absorption spectroscopy shows that upon illumination a thermodynamically stable adduct is formed. We were able to confirm the structure of the adduct by introducing <sup>13</sup>C-labelled 5-deazaFMN isotopologues in solution NMR experiments. Dark-adapted state recovery can be photo-induced, providing a photoswitch that is easy to manipulate. The robust photocycle is repeatable without significant loss. Based on the data presented we propose the system as an alternative to wild-type AsLOV2 for applications in optogenetics.

Received 9th July 2024,  
 Accepted 5th November 2024

DOI: 10.1039/d4cp02714k

rsc.li/pccp

## 1 Introduction

Chromophores of blue-light sensitive proteins comprise *p*-coumaric acid utilised in xanthopsins such as the photoactive yellow protein,<sup>1</sup> retinal found in channelrhodopsins<sup>2</sup> and in sensory rhodopsins,<sup>3</sup> as well as various flavin derivatives that are non-covalently bound to BLUF (“blue light using FAD”) domains, cryptochromes and LOV (“light, oxygen, voltage”) domain-based proteins.<sup>4–9</sup> The latter proteins are ubiquitous in all kinds of organisms.<sup>3,10,11</sup> Following their initial description in phototropin (phot) from *Arabidopsis*<sup>12</sup> they were identified in a number of plant-based (Zeitlupe-family, LOV/LOV protein), bacterial (YtvA, LOV HK, SL2, LovK), fungal (VVD, WC-1) and algal (aureochrome) proteins, see<sup>10,13–15</sup> for reviews. Phots are a notable exception among this group of proteins as they contain two LOV domains. LOV domains bind flavin mononucleotide (FMN) as the redox-active cofactor in a globular  $\alpha/\beta$  fold, along with C- and N-terminal helices.<sup>11</sup> These proteins are responsible for a variety of physiological functions

using blue light as a trigger signal, including phototropism, leaf expansion, gene expression, stomatal opening and chloroplast accumulation.<sup>16</sup> In most cases, the ultimate unfolding of the C-terminal helix (J $\alpha$  helix) after light excitation is responsible for activating the respective effector domain.<sup>11</sup>

The unfolding of the J $\alpha$  helix is a well-defined structural alteration in LOV domains, such as phot1 LOV2 from *Avena sativa* (As), which therefore finds frequent application as a photoswitch in optogenetics.<sup>9,17</sup> Peptides or proteins fused to the J $\alpha$  helix of the LOV domain can be controlled by photo-activation.<sup>18</sup> This technique provides regulation of biological processes such as cell signalling, gene expression, genome editing, protein stabilisation or localisation.<sup>19,20</sup>

The reversible photocycle of the wild-type LOV protein involves the adduct formation between the FMN cofactor and a conserved cysteine residue.<sup>21,22</sup> The mechanism of this cycle, ultimately leading to structural changes in the terminal helices as mentioned above,<sup>23,24</sup> is still not entirely understood. The dark-adapted state protein LOV<sub>445</sub> has its absorbance maximum in the blue light regime at 445 nm. Upon light excitation, the fully oxidised FMN cofactor is transferred to an excited singlet state. Subsequent intersystem crossing (ISC) leads to a triplet state with an absorbance maximum at approximately 660 nm.<sup>5,11,25</sup> Unlike suggested in earlier works,<sup>25,26</sup> recent studies indicate that the adduct formation proceeds without prior protonation of N5 of the FMN by the neighbouring cysteine.<sup>27–29</sup> The adduct LOV<sub>390</sub> forms within a few seconds<sup>25,30</sup> *via* a C4a–S bond, as shown by NMR spectroscopy<sup>31</sup> and X-ray structure analysis.<sup>22</sup> It is hypothesised

<sup>a</sup> Institut für Physikalische Chemie, Albert-Ludwigs-Universität Freiburg, Albertstr. 21, 79104 Freiburg, Germany. E-mail: stefan.weber@pc.uni-freiburg.de

<sup>b</sup> Institut für Lebensmittelchemie, Universität Hamburg, Grindelallee 117, 20146 Hamburg, Germany

<sup>c</sup> TUM School of Natural Sciences, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4cp02714k>

‡ These authors contributed equally to this work.





containing 300 mM NaCl, 20 mM imidazole, 0.02% sodium azide (buffer A) with DNase I (0.1 mg). The mixture was treated for 30 s with the sonicator Sonoplus HD4100 (Bandelin, Berlin, Germany) at 50% of its maximal power and then passed through a French press (Continuous Flow Cell Disruptor CF1, Northants, UK). Cell debris was removed by centrifugation, and the supernatant was placed on the top of a chelating Sepharose column (Ni<sup>2+</sup> form, 1 × 8 cm) that had been equilibrated with the same buffer. The column was washed with buffer A (5 column volumes) and with buffer A containing 6 M guanidine hydrochloride until the effluent became colourless (normally 3–4 column volumes). Subsequently, the column was washed with three column volumes of buffer A. A solution (6 mL) of the respective 5-deazaFMN derivative (2–4 mM) in buffer A was allowed to circulate through the column overnight at 4 °C. The column was washed from the unbound ligand with buffer A (7 column volumes) and the protein was eluted with buffer A containing 0.2 M imidazole. The yellow-green fractions were combined and dialysed with 50 mM K/Na phosphate, pH 7.0, 0.02% NaN<sub>3</sub>.

## 2.2 Spectroscopy

**2.2.1 UV/vis spectroscopy.** For UV/vis measurements, a UV-2450 spectrometer (Shimadzu, Kyōto, Japan) and cuvettes of the type 105.250 (Hellma, Müllheim, Germany) were employed. The measurements were conducted at 277 K. Protein samples were prepared in 50 mM K/Na phosphate, pH 7.0, 0.02% NaN<sub>3</sub> and degassed three times using a freeze–thaw cycle. For illumination of the sample, an optical fibre (Streppel Glasfaser-Optik, Wermelskirchen, Germany) and two LEDs (Thorlabs GmbH, Bergkirchen, Germany) were used: M340L4 at an operation current strength of 0.7 A, corresponding to 1.4 mW measured after the optical fibre, for the illumination at 341 nm and M405L3 at an operation current strength of 0.15 A, corresponding to 4.2 mW measured after the optical fibre, for the illumination at 405 nm. Extinction coefficients were determined using a V-770 spectrometer (JASCO Inc., Easton, MD, USA) and a cuvette of the type 18/Q/10 (Starna GmbH, Pfungstadt, Germany). Spectra were smoothed using a Savitzky–Golay filter.

**2.2.2 NMR spectroscopy.** NMR spectra of the precursors and 5-deazaflavins were acquired using Avance 400 MHz and DRX 500 MHz NMR spectrometers (Bruker, Ettlingen, Germany). Chemical shifts were reported using solvent signals as internal standards (CD<sub>3</sub>OD:  $\delta$  (H) = 3.31 ppm,  $\delta$  (C) = 49.00 ppm; DMSO-*d*<sub>6</sub>:  $\delta$  (H) = 2.50 ppm,  $\delta$  (C) = 39.52 ppm; CDCl<sub>3</sub>:  $\delta$  (H) = 7.26 ppm,  $\delta$  (C) = 77.16 ppm).<sup>68</sup>

NMR experiments with proteins were conducted using an Avance III HD NMR spectrometer (Bruker, Ettlingen, Germany) operating at 14 T/600 MHz and a BBFO broadband probe head optimised for the detection of heteronuclei. All experiments were conducted at 278 K. <sup>13</sup>C experiments were recorded using a 30° probe pulse and power-gated decoupling. Distortionless enhancement by polarisation transfer (DEPT) experiments were recorded using a standard pulse sequence with a 135° probe pulse and  $J_{C,H} = 145$  Hz.<sup>69</sup> For all experiments a recycle delay of

2 s was chosen. The spectra were referenced using the methine and methylene signals of residual glycerol.<sup>70</sup> The samples of AsLOV2 reconstituted with [4a-<sup>13</sup>C<sub>1</sub>]-5-deazaFMN (0.62 mM) and [5-<sup>13</sup>C<sub>1</sub>]-5-deazaFMN (0.58 mM) were prepared in H<sub>2</sub>O/D<sub>2</sub>O (9:1, v:v) containing 50 mM K/Na phosphate, pH 7.0, 0.02% NaN<sub>3</sub>. For measurements of the adduct state, the samples were irradiated for 7 min with a LED (M405L3, Thorlabs GmbH, Bergkirchen, Germany) at 405 nm with 4.2 mW and transferred into a NMR tube.

## 2.3 Determination of extinction coefficient

The extinction coefficient of 5-deazaFMN-LOV2 was determined by unfolding six protein samples of known absorbance through addition of sodium dodecyl sulfate (SDS).<sup>71</sup> The samples were cooled to 277 K. The protein sample (300  $\mu$ L) was added to SDS (13%) dissolved in 50 mM K/Na phosphate, pH 7 (300  $\mu$ L). After 90 min, the maximum absorbance of the samples containing the free cofactor was determined, see Fig. S1 (ESI<sup>†</sup>). The maximum absorbances were averaged and compared with the known extinction coefficient of 5-deazaFMN of  $\epsilon_{396\text{nm}} = 12.000 \text{ mM}^{-1} \text{ cm}^{-1}$ .<sup>72</sup> For verification, a sample of wild-type AsLOV2 was used. By comparison with the extinction coefficient of AsLOV2 ( $13.800 \text{ mM}^{-1} \text{ cm}^{-1}$  at 447 nm<sup>21</sup>), an extinction coefficient of  $12.520 \text{ mM}^{-1} \text{ cm}^{-1}$  for FMN was found (data not shown) which is in accordance to the literature ( $\epsilon_{445\text{nm}} = 12.500 \text{ mM}^{-1} \text{ cm}^{-1}$ ).<sup>73</sup>

## 2.4 Target analysis of the dark-adapted-state-to-adduct-state conversion

The absorbance spectra recorded following intervals of steady-state illumination were analysed through target analysis. A self-written script utilising the Python-based package pyglotaran<sup>74</sup> was employed for the analysis. Species-associated spectra (SAS) were calculated by assuming a mono-exponential decay for the reaction of the dark-adapted state to the adduct state. The spectrum at  $t = 0$  is attributed to the pure dark-adapted state. As the adduct state has a non-zero extinction coefficient at 402 nm, a back reaction to the dark-adapted state at a slower rate is expected. But as an equilibrium is reached under continuous illumination, the reaction back to the dark-adapted state cannot be resolved and was excluded from the model.

## 2.5 Determination of quantum yields

Quantum yields were determined using cuvettes of type 109.004F (Hellma, Müllheim, Germany) with a type SCS1.22 magnetic stirrer (Starna GmbH, Pfungstadt, Germany). For illumination, two LEDs were used: M430L5 (Thorlabs GmbH, Bergkirchen, Germany) operated at 34.0 mW for the illumination at 433 nm and M340L5 (Thorlabs GmbH, Bergkirchen, Germany) operated at 1.4 mW for the illumination at 341 nm as well as an optical fibre (Streppel Glasfaser-Optik, Wermelskirchen, Germany). Quantum yields of adduct formation and dark-adapted state recovery were determined according to a method described by Stadler *et al.*<sup>75</sup> For the adduct formation, the illumination set-up was calibrated to determine the photon flux  $I_0 = 8.17 \times 10^{-5} \text{ mol L}^{-1} \text{ s}^{-1}$  at 433 nm and 277 K.



For calibration, a solution of  $K_3[Fe(C_2O_4)_3] \cdot 3H_2O$  in  $H_2SO_4$  (0.05 M) with known quantum yield<sup>75</sup> was used, see Fig. S2 (ESI†). The solution was bubbled with argon for 5 min prior to measurement. Three samples of 5-deazaFMN-LOV2 in degassed 50 mM K/Na phosphate, pH 7 buffer solution were illuminated. The absorbance changes at the illumination wavelength were fitted with a mono-exponential decay to obtain the decay rate constant  $k_{fit}$ , see Fig. S3 (ESI†). The quantum yield  $\Phi$  was calculated from the averaged decay rate constant, the initial protein concentration  $c_0$ , the initial absorbance at the illumination wavelength  $A'_i$  and  $I_0$ :

$$\Phi = \frac{k_{fit} \times c_0}{I_0 \times (1 - 10^{-A'_i})} \quad (1)$$

For the dark-state recovery, a similar approach yielded the photon flux  $I_0 = 7.51 \times 10^{-7} \text{ mol L}^{-1} \text{ s}^{-1}$  at 341 nm and 277 K. For calibration, a solution of *o*-nitrobenzaldehyd in acetonitrile with known quantum yield<sup>75</sup> was used, see Fig. S4 (ESI†). The measured absorbance changes of two samples of the 5-deazaFMN-LOV2 adduct are depicted in Fig. S5 (ESI†).

## 2.6 Computational methods

For theoretical calculations of absorbance spectra of possible adduct structures using TD-DFT, simplified models for adduct 1, 2a and 2b (see Tables S1–S3 and Fig. S6–S8 for optimised structures, ESI†) were used: 7,8,10-trimethyl-4a-(methylthio)-5,10-dihydropyrimido[4,5-*b*]quinoline-2,4(3*H*,4a*H*)-dione, 7,8,10-trimethyl-5-(methylthio)-5,10-dihydropyrimido[4,5-*b*]quinoline-2,4(1*H*,3*H*)-dione and 7,8,10-trimethyl-5-(methylthio)-5,10-dihydropyrimido[4,5-*b*]quinoline-2,4(3*H*,4a*H*)-dione, respectively. 5-Deazalumiflavin was employed as model for 5-deazaFMN. All geometries were optimised with ORCA 4.0.1.2<sup>76,77</sup> utilising a B3LYP functional<sup>78</sup> and a TZVP basis set.<sup>79,80</sup> The optimised geometries were used as input structures for TD-DFT calculations as well as calculations of chemical shifts, which were conducted *in vacuo* utilising a B3LYP functional as well as a def2-TZVP<sup>81</sup> and def2/J basis set<sup>82</sup> with a RIJCOSX approximation.<sup>83</sup> Trimethylsilane (TMS) was employed as a chemical shift reference.

## 3 Results & discussion

### 3.1 UV/vis characterisation of the photocycle of AsLOV2 reconstituted with 5-deazaFMN

The adduct formation of 5-deazaFMN-LOV2 was monitored by recording absorbance changes under steady-state illumination near its visible absorbance maximum, see Fig. 2. The absorbance maxima at 375 nm, 402 nm and 423 nm decrease with progressing irradiation time while the maximum at 339 nm increases and is gradually shifted to 334 nm. No significant changes in the band shape are visible, apart from a broadening of the fine structure around 334 nm. The gradual disappearance of the long-wavelength absorbance maximum can be attributed to the reduction of the 5-deazaflavin's aromatic system due to adduct formation. After 980 s, 5-deazaFMN-LOV2 has reached a steady state. The adduct state is thermodynamically stable and




Fig. 2 Steady-state illumination of 5-deazaFMN-LOV2 (spectrum of the dark-adapted state in blue). The absorbance changes from blue to orange. The illumination time is indicated for each spectrum. The emission profile of the LED used for illumination is indicated by the light blue area.

shows no significant absorbance changes during several days, see Fig. S9 (ESI†). The dark-adapted state recovery can be photo-induced by illuminating the photoadduct near its UV absorbance maximum, see Fig. 3. The spectral changes indicate that the dark-adapted state can be recovered up to approximately 70%. This incomplete adduct cleavage can be attributed to overlapping absorbance spectra of the dark-adapted state and the adduct state of 5-deazaFMN-LOV2. A quantitative comparison of the absorbance maxima is described in the following section.

To calculate the SAS of the adduct state, the illumination series shown in Fig. S10 (ESI†) was analysed by target analysis. In order to ensure linearity between concentration and absorbance, a maximal optical density lower than 1.0 was chosen for the initial sample. The spectrum before illumination was




Fig. 3 Dark-adapted state recovery by steady-state illumination of the AsLOV2-5-deazaFMN adduct. The absorbance changes from blue to orange. The illumination time is indicated for each spectrum. The emission profile of the LED used for illumination is indicated by the light blue area.






Fig. 4 Absorbance spectra of the dark-adapted (blue) and adduct state (orange) of 5-deazaFMN-LOV2 determined by target analysis as well as the experimentally acquired spectrum of the dark-adapted state (dashed line).

attributed to 5-deazaFMN-LOV2 in its pure dark-adapted state. The subsequent spectra of the illumination series are linear combinations of absorbance spectra of the dark-adapted and adduct state of the protein. Consequently, the SAS of the adduct state acquired by target analysis corresponds to its pure absorbance spectrum, see Fig. 4. The absorbance at 402 nm is significantly decreased while the absorbance at 334 nm is slightly increased compared to the dark-adapted state.

The extinction coefficient  $\epsilon$  of 5-deazaFMN-LOV2 in its dark-adapted state was determined experimentally by unfolding a protein sample and comparing the absorbance maxima of the protein with that of the free cofactor with known extinction coefficient.<sup>72</sup> Comparison of the SAS in Fig. 4 allows the determination of extinction coefficients of both the dark-adapted and adduct states, see Table 1. The extinction coefficient at 334 nm of the adduct state is slightly higher than that of the dark-adapted state leading to simultaneous activation of adduct state and dark-adapted state formation by illumination at this wavelength. Consequently, it is not possible to achieve complete regeneration of the dark-adapted state following adduct formation.

To determine the applicability of the 5-deazaFMN-LOV2 system as a potential photoswitch, the repeatability of consecutive adduct state formations and dark-adapted state recoveries was investigated using UV/vis spectroscopy. Fig. 5 illustrates three illumination cycles during which the absorbance of




Fig. 5 Absorbance of 5-deazaFMN-LOV2 at the visible light (402 nm) and the UV absorbance maximum. As the UV absorbance maximum shifts between 334 nm and 339 nm depending on the state of the protein, the maximal absorbance regardless of wavelength is depicted. Each illumination cycle comprises 100 absorbance measurements. Between each measurement, the sample was illuminated for 20 s by the LED indicated at the top of the graph.

5-deazaFMN-LOV2 at 405 nm and 340 nm were recorded. Initially, the pure dark-adapted state is converted to the adduct state with approximately 90% conversion. The illumination of the adduct state leads to an equilibrium of both states, as explained above, with approximately 70% dark-adapted state regeneration. During the following illumination cycles, the sample oscillates between both states. No signs of sample degradation induced by illumination can be detected, thereby proving the robustness of the photocycle. This is in accordance with findings using *OdAu1a*, which showed a similar repeatability.<sup>49</sup>

Furthermore, the quantum yield of the adduct formation of 5-deazaFMN-LOV2 was determined. By averaging the decay rate constant of three illumination series of 5-deazaFMN-LOV2, a quantum yield of 0.09 was determined, see eqn (1) and Fig. S3 (ESI<sup>†</sup>). For *BsYtvA* a similar value of 0.03–0.05 was found.<sup>48</sup> This result is lower than the quantum yield of *AsLOV2* harboring FMN ( $\Phi = 0.44$ )<sup>21</sup> which indicates that the native cofactor is more effective in inducing the adduct formation. For completeness, the dark-adapted state recovery was also analysed, although this method only provides a lower limit of the quantum yield due to the simultaneous activation of dark-adapted state recovery and adduct formation at 340 nm. By averaging the decay rate constants of two samples of the 5-deazaFMN-LOV2 adduct, a quantum yield of 0.35 was determined, see Fig. S5 (ESI<sup>†</sup>).

### 3.2 Characterisation of the adduct formation using NMR and TD-DFT

The exchange of N by C–H at position 5 in 5-deazaFMN allows for different bond formations between the cofactor and the cysteinyl residue upon adduct formation. Similar to the wild-type protein carrying FMN, C5 can be protonated and a bond between C4a and the thiol group of cysteine can be formed, see adduct 1 in Fig. 6. It is also conceivable that C5 forms a bond

Table 1 Extinction coefficients of the visible and UV absorbance maxima of 5-deazaFMN-LOV2 in the dark-adapted state and adduct state. The values for the dark-adapted state were determined as described in the Experimental section. The values for the adduct state were determined using target analysis

	$\epsilon_{\max}/(\text{mM cm})^{-1} (\lambda/\text{nm})$	
Dark-adapted state	$14.4 \pm 0.7$ (339)	$15.3 \pm 0.7$ (402)
Adduct state	$17.3 \pm 0.8$ (334)	$0.40 \pm 0.02$ (402)






Fig. 6 Proposed adduct formations of 5-deazaFMN and Cys450 in AsLOV2 with  $R_1 = \text{ribityl-5'-PO}_3\text{H}_2$  and  $R_2 = \text{Cys450}$ . The bond formation between the cysteinyl thiol group and C4a (adduct 1) or C5 (adducts 2a and 2b) of 5-deazaFMN is considered.

with the thiol group. In this instance, N1 and C4a are potential protonation sites, corresponding to adducts 2a and 2b, respectively.

A first approach to solving the adduct structure is given by comparing the absorbance spectrum of the 5-deazaFMN-LOV2 adduct to predictions from TD-DFT for the proposed chemical structures shown in Fig. 6. In order to achieve this objective, 5-deazalumiflavin was employed as a simplified reference model for the 5-deazaFMN cofactor. TD-DFT calculations *in vacuo* yielded the absorbance spectra depicted in Fig. 7 that are compared to the experimental absorbance spectra of 5-deazaFMN-LOV2 before illumination and in its adduct state after illumination.




Fig. 7 Normalised absorbance spectra calculated using TD-DFT for models of adduct 1 (orange), adduct 2a (yellow) and adduct 2b (red) of 5-deazaFMN-LOV2 compared to a model of 5-deazalumiflavin (reference, blue). The experimental absorbance spectrum of 5-deazaFMN-LOV2 before and after 980 s of illumination at 403 nm is shown as a light blue and light orange area, respectively.

A comparison of the experimental spectrum of the dark-adapted state with the calculated spectrum of 5-deazalumiflavin reveals a difference of absorbance maxima of 25 nm. We assume that this shift is mainly due to solvent effects that are not taken into account by the TD-DFT calculation *in vacuo*. The absorbance maxima of adducts 2a and 2b coincide at 293–294 nm, whereas the absorbance maximum of adduct 1 is shifted to 317 nm. These results clearly distinguish the different bond models, C4a-S and C5-S, from one another. The experimental absorbance maximum of 334 nm is in better agreement with the adduct model of a C4a-S bond. The shift between experimental and calculated spectrum amounts to 17 nm, which is comparable to the shift of the reference. This comparison suggests that adduct 1 corresponds to the structure of the 5-deazaFMN-LOV2 adduct.

To gather unambiguous experimental evidence, the  $^{13}\text{C}$  NMR shift changes of 5-deazaFMN-LOV2 after illumination were combined with the signal patterns of DEPT135 experiments. LOV2 was reconstituted with two 5-deazaFMN isotopologues  $^{13}\text{C}$ -labelled either at position 4a or position 5. Fig. 8 and 9 illustrate spectra of the dark-adapted state (orange), the adduct state (blue) and the adduct state using a DEPT135 pulse sequence (green) for  $[4\text{-}^{13}\text{C}_1]\text{-5-deazaFMN-LOV2}$  and  $[5\text{-}^{13}\text{C}_1]\text{-5-deazaFMN-LOV2}$ , respectively. Table 2 presents a summary of the experimental and calculated chemical shift values. In the spectra of the dark-adapted state, chemical shifts for C4a and C5 of 111.12 ppm and 143.61 ppm are observed. The signals were assigned according to the chemical shifts obtained from the respective cofactor in aqueous solution, 112.04 ppm and 142.93 ppm for C4a and C5, respectively, see Fig. S11 (ESI $^\dagger$ ). DFT calculations predict values of 121.8 ppm and 145.3 ppm for these positions in the simplified model of 5-deazalumiflavin, which corresponds reasonably well to the experimental data.




Fig. 8  $^{13}\text{C}$  NMR spectra of LOV2 reconstituted with  $[4\text{-}^{13}\text{C}_1]\text{-5-deazaFMN}$ : before illumination (orange, 71 680 scans), after illumination (blue, 61 440 scans) and after illumination using the DEPT135 sequence (green, 49 152 scans). Signals of residual glycerol are denoted with asterisks.






Fig. 9  $^{13}\text{C}$  NMR spectra of LOV2 reconstituted with  $[5-^{13}\text{C}_1]$ -5-deazaFMN: before illumination (orange, 71 680 scans), after illumination (blue, 40 960 scans) and after illumination using the DEPT135 sequence (green, 40 960 scans). Signals of residual glycerol are denoted with asterisks.

Table 2  $^{13}\text{C}$  chemical shifts in ppm of C4a and C5 in 5-deazaFMN-LOV2 in the dark-adapted and adduct state. Chemical shifts calculated by DFT corresponding to the suggested adduct models are included

Model/sample	$\delta(\text{C4a})/\text{ppm}$	$\delta(\text{C5})/\text{ppm}$
Dark-adapted state (exp.)	111.12	143.61
5-DeazaFMN in solution (exp.)	112.04	142.93
Dark-adapted state (DFT)	121.8	145.3
Adduct state (exp.)	44.82	33.70
Adduct 1 (DFT)	51.8	31.5
Adduct 2a (DFT)	93.1	48.5
Adduct 2b (DFT)	50.2	53.3

Differences in chemical shifts, mainly for C4a, can be attributed to the DFT calculations being performed *in vacuo*.

Following illumination, the signals of both C4a and C5 are observed to shift to 44.82 ppm and 33.70 ppm, respectively. The chemical shift of C4a is found to be consistent with the predictions for adduct 1 (51.8 ppm) and 2b (50.2 ppm) but in disagreement with the predicted value for adduct 2a (93.1 ppm). The chemical shift of C5 indicates the formation of adduct 1 (31.5 ppm) which shows better correspondence than adduct 2a (48.5 ppm) and adduct 2b (53.3 ppm). These results are confirmed by the signal phases of C4a and C5 obtained from DEPT135 experiments which differentiate methyl ( $\text{CH}_3$ ), methylene ( $\text{CH}_2$ ) and methine ( $\text{CH}$ ) resonances. For  $\text{CH}$  and  $\text{CH}_3$ , absorptive resonances are expected, while for  $\text{CH}_2$ , the resonance is emissive. Quaternary carbons do not show any resonance in DEPT135 spectra.<sup>69,84</sup> The DEPT135 spectra in Fig. 8 and 9 show an emissive signal for C5 and no signal for C4a. We can conclude that C4a is a quaternary carbon and C5 a methylene group in the adduct state. These conditions can only be met by adduct 1, where C4a is a quaternary carbon by forming the sulfide bond and C5 is additionally protonated.

These findings prove unambiguously that the adduct state of 5-deazaFMN-LOV2 is formed *via* a C4a-S bond. To the best of our knowledge, this has not yet been demonstrated experimentally under physiological conditions.

This result is in accordance with findings for *OdAu1a* and *BsYtvA* reconstituted with 5-deazaFMN,<sup>48,49</sup> which provides strong evidence that LOV domains from different organisms share similar behaviour towards the 5-deazaFMN cofactor. Extending cofactor replacement studies to more LOV domains are required to prove this hypothesis. This could result in the identification of a novel subgroup of photoswitches that are easier to manipulate between dark-adapted and adduct states than the respective wild-type LOV domains. It would be advantageous to achieve a higher conversion between the adduct state and reformation of the dark-adapted state. For this purpose, a minimal overlap of absorption between dark-adapted and adduct states in the UV and visible region is essential. It is possible that 5-deazaFMN cofactors that are shifted bathochromically could provide this feature to a certain degree.

Incorporating artificial cofactors by refolding of the protein may not be a successful approach for optogenetic experiments or other applications. An *in vivo* synthesis of the artificial cofactor bound to the LOV domain would be desirable. The expression of LOV1 from *Chlamydomonas reinhardtii* reconstituted with roseoflavin in *E. coli* was successfully demonstrated by Mathes *et al.*<sup>85</sup> The *E. coli* strain was modified to express a riboflavin transporter to take up the riboflavin analogue from the medium. Additionally, a riboflavin biosynthetic gene was removed from the strain to completely prevent this pathway. This procedure could be modified by using commercially available 5-deazariboflavin to synthesise the 5-deazaFMN-LOV2 system *in vivo*. Furthermore, the elucidation of the biosynthetic pathway of the natural 5-deazaflavin cofactor  $\text{F}_{420}$  enabled the high-yield production of this cofactor in *E. coli*.<sup>86,87</sup> Although not readily applicable, these advances may ultimately lead to the biosynthetic expression of LOV proteins reconstituted with natural 5-deazaflavin cofactors.

When used as an optogenetic tool, the effector domain is fused to the  $\text{J}\alpha$  helix in *AsLOV2*. For the presented system to be applicable, the unfolding of this helix must remain functional after cofactor exchange. The cofactor exchange in *OdAu1a* blocks the protonation of N5 of the cofactor which is thought to be an important step in the signalling pathway. Ultimately, the light-induced dimerisation is prohibited in 5-deazaFMN-*OdAu1a*.<sup>49</sup> These results raise the question of whether a similar effect of cofactor exchange can be found in *AsLOV2* which would reduce the applicability of the system. Further experiments are needed to clarify the consequences of reconstituting *AsLOV2* with 5-deazaFMN.

## 4 Conclusions

This comprehensive study, which combines optical and NMR spectroscopy, investigates the adduct formation of *AsLOV2*



reconstituted with 5-deazaFMN providing mechanistic detail. The NMR study, combined with DFT calculations, provides clear evidence of photo-induced bond formation between C4a of 5-deazaFMN and the cysteinyl thiol group. To our knowledge, this is the first study to use DEPT pulse sequences to elucidate the structure of protein adducts. The absorption properties of the resulting 5-deazaFMN-LOV2 adduct are compared with those of its dark-adapted state. Furthermore, we demonstrate the robustness of the cycle between the dark-adapted state and the adduct state, which is an important prerequisite for the applicability of the system. We therefore propose this photoswitch system as a promising alternative to the wild-type AsLOV2.

## Author contributions

Conceptualisation: J. W., S. P., A. B., M. F. and S. W.; data curation: S. P. and J. W.; formal analysis: S. P., J. W. and J. C.; funding acquisition: M. F. and S. W.; investigation: S. P., J. W. and J. C.; methodology: S. P., J. W. and S. W.; project administration: M. F. and S. W.; resources: S. P., J. W., J. C., B. I., A. B., M. F., S. W.; software: S. P.; supervision: A. B., M. F. and S. W.; validation: S. P., J. W. and J. C.; visualisation: S. P.; writing – original draft: S. P., B. I. and S. W.; writing – review & editing: J. W., B. I., A. B. and M. F.

## Data availability

The data supporting this article have been included as part of the ESI.†

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank Lars Kuhn for providing technical support and for helpful discussions. SW thanks the SIBW/DFG for financing NMR instrumentation that is operated within the MagRes Center of the Albert-Ludwigs-Universität Freiburg (Germany). SW and MF acknowledge financial support from the Deutsche Forschungsgemeinschaft (DFG) (project number 459493567: WE 2376/12-1 and FI824/13-1).

## Notes and references

- 1 T. E. Meyer, *Biochim. Biophys. Acta, Bioenerg.*, 1985, **806**, 175–183.
- 2 E. B. Purcell and S. Crosson, *Curr. Opin. Microbiol.*, 2008, **11**, 168–178.
- 3 P. Hegemann, *Annu. Rev. Plant Biol.*, 2008, **59**, 167–189.
- 4 T. Kottke, A. Xie, D. S. Larsen and W. D. Hoff, *Annu. Rev. Biophys.*, 2018, **47**, 291–313.
- 5 A. Losi and W. Gärtner, *Photochem. Photobiol.*, 2017, **93**, 141–158.
- 6 S.-Y. Park and J. R. H. Tame, *Biophys. Rev.*, 2017, **9**, 169–176.
- 7 S. Masuda, *Plant Cell Physiol.*, 2013, **54**, 171–179.
- 8 I. Chaves, R. Pokorny, M. Byrdin, N. Hoang, T. Ritz, K. Brettel, L.-O. Essen, G. T. J. van der Horst, A. Batschauer and M. Ahmad, *Annu. Rev. Plant Biol.*, 2011, **62**, 335–364.
- 9 A. Losi, K. H. Gardner and A. Möglich, *Chem. Rev.*, 2018, **118**, 10659–10709.
- 10 J. Herrou and S. Crosson, *Nat. Rev. Microbiol.*, 2011, **9**, 713–723.
- 11 A. Flores-Ibarra, R. N. A. Maia, B. Olsasz, J. R. Church, G. Gotthard, I. Schapiro, J. Heberle and P. Nogly, *J. Mol. Biol.*, 2024, **436**, 168356.
- 12 E. Huala, P. W. Oeller, E. Liscum, I. S. Han, E. Larsen and W. R. Briggs, *Science*, 1997, **278**, 2120–2123.
- 13 N. Suetsugu and M. Wada, *Plant Cell Physiol.*, 2013, **54**, 8–23.
- 14 J. M. Christie, L. Blackwood, J. Petersen and S. Sullivan, *Plant Cell Physiol.*, 2015, **56**, 401–413.
- 15 J. M. Christie and M. D. Zurbriggen, *New Phytol.*, 2021, **229**, 3108–3115.
- 16 A. Losi and W. Gärtner, *Annu. Rev. Plant Biol.*, 2012, **63**, 49–72.
- 17 M. D. Hoffmann, F. Bubeck, R. Eils and D. Niopek, *Adv. Biosyst.*, 2018, **2**, 1800098.
- 18 A. C. McCue and B. Kuhlman, *Curr. Opin. Struct. Biol.*, 2022, **74**, 102377.
- 19 T. Iwata and S. Masuda, in *Optogenetics. Light-Sensing Proteins and Their Applications in Neuroscience and Beyond*, ed. H. Yawo, H. Kandori, A. Koizumi and R. Kageyama, Springer, Singapore, 2nd edn, 2021, ch. 11, pp. 189–206.
- 20 X. Li, C. Zhang, X. Xu, J. Miao, J. Yao, R. Liu, Y. Zhao, X. Chen and Y. Yang, *Nucleic Acids Res.*, 2020, **48**, e33.
- 21 M. Salomon, J. M. Christie, E. Knieb, U. Lempert and W. R. Briggs, *Biochemistry*, 2000, **39**, 9401–9410.
- 22 S. Crosson and K. Moffat, *Plant Cell*, 2002, **14**, 1067–1075.
- 23 J. P. Zayner, C. Antoniou and T. R. Sosnick, *J. Mol. Biol.*, 2012, **419**, 61–74.
- 24 S. M. Harper, L. C. Neil and K. H. Gardner, *Science*, 2003, **301**, 1541–1544.
- 25 T. E. Swartz, S. B. Corchnoy, J. M. Christie, J. W. Lewis, I. Szundi, W. R. Briggs and R. A. Bogomolni, *J. Biol. Chem.*, 2001, **276**, 36493–36500.
- 26 J. T. M. Kennis, S. Crosson, M. Gauden, I. H. M. van Stokkum, K. Moffat and R. van Grondelle, *Biochemistry*, 2003, **42**, 3385–3392.
- 27 C. W. M. Kay, E. Schleicher, A. Kuppig, H. Hofner, W. Rüdiger, M. Schleicher, M. Fischer, A. Bacher, S. Weber and G. Richter, *J. Biol. Chem.*, 2003, **278**, 10973–10982.
- 28 E. Schleicher, R. M. Kowalczyk, C. W. M. Kay, P. Hegemann, A. Bacher, M. Fischer, R. Bittl, G. Richter and S. Weber, *J. Am. Chem. Soc.*, 2004, **126**, 11067–11076.
- 29 C. Thöing, A. Pfeifer, S. Kakorin and T. Kottke, *Phys. Chem. Chem. Phys.*, 2013, **15**, 5916–5926.
- 30 W. Holzer, A. Penzkofer, M. Fuhrmann and P. Hegemann, *Photochem. Photobiol.*, 2002, **75**, 479–487.



- 31 M. Salomon, W. Eisenreich, H. Dürr, E. Schleicher, E. Knieb, V. Massey, W. Rüdiger, F. Müller, A. Bacher and G. Richter, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 12357–12361.
- 32 C. Neiß and P. Saalfrank, *Photochem. Photobiol.*, 2003, **77**, 101–109.
- 33 C. Bauer, C.-R. Rabl, J. Heberle and T. Kottke, *Photochem. Photobiol.*, 2011, **87**, 548–553.
- 34 R. J. Kutta, K. Magerl, U. Kensy and B. Dick, *Photochem. Photobiol. Sci.*, 2015, **14**, 288–299.
- 35 M. Kasahara, T. E. Swartz, M. A. Olney, A. Onodera, N. Mochizuki, H. Fukuzawa, E. Asamizu, S. Tabata, H. Kanegae, M. Takano, J. M. Christie, A. Nagatani and W. R. Briggs, *Plant Physiol.*, 2002, **129**, 762–773.
- 36 B. D. Zoltowski, B. Vaccaro and B. R. Crane, *Nat. Chem. Biol.*, 2009, **5**, 827–834.
- 37 S. Raffelberg, M. Mansurova, W. Gärtner and A. Losi, *J. Am. Chem. Soc.*, 2011, **133**, 5346–5356.
- 38 H. Guo, T. Kottke, P. Hegemann and B. Dick, *Biophys. J.*, 2005, **89**, 402–412.
- 39 D. Nozaki, T. Iwata, T. Ishikawa, T. Todo, S. Tokutomi and H. Kandori, *Biochemistry*, 2004, **43**, 8373–8379.
- 40 A. Möglich and K. Moffat, *J. Mol. Biol.*, 2007, **373**, 112–126.
- 41 B. D. Zoltowski, C. Schwerdtfeger, J. Widom, J. J. Loros, A. M. Bilwes, J. C. Dunlap and B. R. Crane, *Science*, 2007, **316**, 1054–1057.
- 42 A. T. Vaidya, C.-H. Chen, J. C. Dunlap, J. J. Loros and B. R. Crane, *Sci. Signaling*, 2011, **4**, ra50.
- 43 S. Endres, J. Granzin, F. Circolone, A. Stadler, U. Krauss, T. Drepper, V. Svensson, E. Knieps-Grünhagen, A. Wirtz, A. Cousin, P. Tielen, D. Willbold, K.-E. Jaeger and R. Batra-Safferling, *BMC Microbiol.*, 2015, **15**, 30.
- 44 E. Peter, B. Dick and S. A. Baeurle, *Proteins: Struct., Funct., Bioinf.*, 2012, **80**, 471–481.
- 45 A. Ganguly, W. Thiel and B. R. Crane, *J. Am. Chem. Soc.*, 2017, **139**, 2972–2980.
- 46 P. Hemmerich and V. Massey, *FEBS Lett.*, 1977, **84**, 5–21.
- 47 J. Fisher, R. Spencer and C. Walsh, *Biochemistry*, 1976, **15**, 1054–1064.
- 48 M. R. Silva-Junior, M. Mansurova, W. Gärtner and W. Thiel, *ChemBioChem*, 2013, **14**, 1648–1661.
- 49 M. E. Kalvaitis, L. A. Johnson, R. J. Mart, P. Rizkallah and R. K. Allemann, *Biochemistry*, 2019, **58**, 2608–2616.
- 50 Q. Su, P. A. Boucher and S. E. Rokita, *Angew. Chem., Int. Ed.*, 2017, **56**, 10862–10866.
- 51 C. T. Walsh, *Annu. Rev. Biochem.*, 2017, **86**, 1–19.
- 52 M. V. Shah, J. Antoney, S. W. Kang, A. C. Warden, C. J. Hartley, H. Nazem-Bokae, C. J. Jackson and C. Scott, *Catalysts*, 2019, **9**, 868.
- 53 H. J. Duchstein, H. Fenner, P. Hemmerich and W. R. Knappe, *Eur. J. Biochem.*, 1979, **95**, 167–181.
- 54 M. Goldberg, I. Pecht, H. E. A. Kramer, R. Traber and P. Hemmerich, *Biochim. Biophys. Acta, Gen. Subj.*, 1981, **673**, 570–593.
- 55 P. F. Heelis, B. J. Parsons, G. O. Phillips and A. J. Swallow, *Int. J. Radiat. Biol.*, 1989, **55**, 557–562.
- 56 J. Wörner, S. Panter, B. Illarionov, A. Bacher, M. Fischer and S. Weber, *Angew. Chem., Int. Ed.*, 2023, **62**, e202309334.
- 57 S. Hecht, G. Richter, A. Bacher, M. Joshi, W. Röhmisch, G. Greiner, R. Frank, S. Weber, W. Eisenreich and M. Fischer, in *Flavins and Flavoproteins 2005*, ed. T. Nishino, R. Miura, M. Tanokura and K. Fukui, ARchiTect Inc., Tokyo, Japan, 1st edn, 2005, pp. 569–574.
- 58 T. Kottke, B. Dick, R. Fedorov, I. Schlichting, R. Deutzmann and P. Hegemann, *Biochemistry*, 2003, **42**, 9854–9862.
- 59 S. B. Corchnoy, T. E. Swartz, J. W. Lewis, I. Szundi, W. R. Briggs and R. A. Bogomolni, *J. Biol. Chem.*, 2003, **278**, 724–731.
- 60 Y. I. Wu, D. Frey, O. I. Lungu, A. Jaehrig, I. Schlichting, B. Kuhlman and K. M. Hahn, *Nature*, 2009, **461**, 104–108.
- 61 M. Yazawa, A. M. Sadaghiani, B. Hsueh and R. E. Dolmetsch, *Nat. Biotechnol.*, 2009, **27**, 941–945.
- 62 A. Möglich, R. A. Ayers and K. Moffat, *J. Mol. Biol.*, 2009, **385**, 1433–1444.
- 63 D. Strickland, X. Yao, G. Gawlak, M. K. Rosen, K. H. Gardner and T. R. Sosnick, *Nat. Methods*, 2010, **7**, 623–626.
- 64 D. E. O'Brien, L. T. Weinstock and C. C. Cheng, *J. Heterocycl. Chem.*, 1970, **7**, 99–105.
- 65 K. Sanada, H. Ube and M. Shionoya, *J. Am. Chem. Soc.*, 2016, **138**, 2945–2948.
- 66 S. S. Neti and C. D. Poulter, *J. Org. Chem.*, 2016, **81**, 5087–5092.
- 67 E. E. Carlson and L. L. Kiessling, *J. Org. Chem.*, 2004, **69**, 2614–2617.
- 68 H. E. Gottlieb, V. Kotlyar and A. Nudelman, *J. Org. Chem.*, 1997, **62**, 7512–7515.
- 69 D. Doddrell, D. Pegg and M. Bendall, *J. Magn. Reson.*, 1982, **48**, 323–327.
- 70 J. Lu, P. Wang, Q. Wang, Y. Wang and M. Jiang, *Molecules*, 2018, **23**, 1177.
- 71 M. C. McKean, J. D. Beckmann and F. E. Frerman, *J. Biol. Chem.*, 1983, **258**, 1866–1870.
- 72 R. Spencer, J. Fisher and C. Walsh, *Biochemistry*, 1976, **15**, 1043–1053.
- 73 J. Koziol, *Methods Enzymol.*, 1971, **18**, 253–285.
- 74 I. H. M. van Stokkum, J. Weißenborn, S. Weigand and J. J. Snellenburg, *Photochem. Photobiol. Sci.*, 2023, **22**, 2413–2431.
- 75 E. Stadler, A. Eibel, D. Fast, H. Freißmuth, C. Holly, M. Wiech, N. Moszner and G. Gescheidt, *Photochem. Photobiol. Sci.*, 2018, **17**, 660–669.
- 76 F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2012, **2**, 73–78.
- 77 F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2018, **8**, e1327.
- 78 A. D. Becke, *J. Chem. Phys.*, 1993, **98**, 5648–5652.
- 79 A. Schäfer, H. Horn and R. Ahlrichs, *J. Chem. Phys.*, 1992, **97**, 2571–2577.
- 80 A. Schäfer, C. Huber and R. Ahlrichs, *J. Chem. Phys.*, 1994, **100**, 5829–5835.
- 81 F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297–3305.



- 82 F. Weigend, *Phys. Chem. Chem. Phys.*, 2006, **8**, 1057–1065.
- 83 F. Neese, F. Wennmohs, A. Hansen and U. Becker, *Chem. Phys.*, 2009, **356**, 98–109.
- 84 M. R. Bendall, D. M. Doddrell and D. T. Pegg, *J. Am. Chem. Soc.*, 1981, **103**, 4603–4605.
- 85 T. Mathes, C. Vogl, J. Stolz and P. Hegemann, *J. Mol. Biol.*, 2009, **385**, 1511–1518.
- 86 G. Bashiri, J. Antoney, E. N. M. Jirgis, M. V. Shah, B. Ney, J. Copp, S. M. Stuteley, S. Sreebhavan, B. Palmer, M. Middleditch, N. Tokuriki, C. Greening, C. Scott, E. N. Baker and C. J. Jackson, *Nat. Commun.*, 2019, **10**, 1558.
- 87 M. V. Shah, H. Nazem-Bokaei, J. Antoney, S. W. Kang, C. J. Jackson and C. Scott, *Sci. Rep.*, 2021, **11**, 21774.

